Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome | MicrobiomeTrials← Back to trialsNCT07729592
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07Est. Completion: 2029-07
Enrollment target: 44 participants Other microbiome trials you might be interested in
Post-Hepatectomy Liver FailureLiver FailureLiver NeoplasmsCarcinoma, HepatocellularLiver MetastasesPostoperative ComplicationsHepatic Congestion
Removing a large part of the liver (major hepatectomy) can cure primary and secondary liver cancers, but it carries the …
Minya, EgyptEst. completion Apr 30, 2028
Cancer Harboring BRAF AlterationsHGGLGG
Solid Tumors
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF a…
Beverly Hills, United StatesEst. completion Dec 31, 2027